Enlivex Therapeutics Ltd. (ENLV)
NASDAQ: ENLV · Real-Time Price · USD
0.8260
+0.0010 (0.12%)
At close: Dec 23, 2025, 1:00 PM EST
0.8151
-0.0109 (-1.32%)
Pre-market: Dec 24, 2025, 6:03 AM EST
Enlivex Therapeutics Employees
Enlivex Therapeutics had 71 employees as of December 31, 2021. The number of employees increased by 21 or 42.00% compared to the previous year.
Employees
71
Change (1Y)
21
Growth (1Y)
42.00%
Revenue / Employee
n/a
Profits / Employee
-$178,887
Market Cap
20.07M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2021 | 71 | 21 | 42.00% |
| Dec 31, 2020 | 50 | 14 | 38.89% |
| Dec 31, 2019 | 36 | 5 | 16.13% |
| Dec 31, 2018 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ENLV News
- 19 days ago - Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development - GlobeNewsWire
- 4 weeks ago - Enlivex Appoints former Italy Prime Minister Matteo Renzi to Board of Directors - PRNewsWire
- 4 weeks ago - Enlivex Announces $212,000,000 Private Placement to Initiate World's First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board - GlobeNewsWire
- 4 weeks ago - Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis - GlobeNewsWire
- 2 months ago - Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025 - GlobeNewsWire
- 3 months ago - D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program - GlobeNewsWire
- 3 months ago - Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results - GlobeNewsWire
- 3 months ago - Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis - GlobeNewsWire